These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 1394697

  • 1. Synthesis of trans-4-aminomethylcyclohexanecarbonyl-L- and -D-phenylalanine-4-carboxymethylanilide and examination of their inhibitory activity against plasma kallikrein.
    Wanaka K, Okada Y, Tsuda Y, Okamoto U, Hijikata-Okunomiya A, Okamoto S.
    Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1814-7. PubMed ID: 1394697
    [Abstract] [Full Text] [Related]

  • 2. Development of plasma kallikrein selective inhibitors.
    Okada Y, Tsuda Y, Tada M, Wanaka K, Hijikata-Okunomiya A, Okamoto U, Okamoto S.
    Biopolymers; 1999 Jul; 51(1):41-50. PubMed ID: 10380351
    [Abstract] [Full Text] [Related]

  • 3. Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship.
    Teno N, Wanaka K, Okada Y, Taguchi H, Okamoto U, Hijikata-Okunomiya A, Okamoto S.
    Chem Pharm Bull (Tokyo); 1993 Jun; 41(6):1079-90. PubMed ID: 8370108
    [Abstract] [Full Text] [Related]

  • 4. Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: the importance of the peptide backbone.
    Fukumizu A, Tsuda Y, Wanaka K, Tada M, Okamoto S, Hijikata-Okunomiya A, Okada Y.
    Chem Pharm Bull (Tokyo); 1999 Aug; 47(8):1141-4. PubMed ID: 10478469
    [Abstract] [Full Text] [Related]

  • 5. Design of plasma kallikrein inhibitors: functional and structural requirements of plasma kallikrein inhibitors.
    Tsuda Y, Wanaka K, Tada M, Okamoto S, Hijikata-Okunomiya A, Okada Y.
    Chem Pharm Bull (Tokyo); 1998 Mar; 46(3):452-7. PubMed ID: 9549887
    [Abstract] [Full Text] [Related]

  • 6. Effect of a highly selective plasma-kallikrein synthetic inhibitor on contact activation relating to kinin generation, coagulation and fibrinolysis.
    Wanaka K, Okamoto S, Bohgaki M, Hijikata-Okunomiya A, Naito T, Okada Y.
    Thromb Res; 1990 Mar 15; 57(6):889-95. PubMed ID: 2382257
    [Abstract] [Full Text] [Related]

  • 7. Development of selective inhibitors against plasma kallikrein.
    Teno N, Wanaka K, Okada Y, Tsuda Y, Okamoto U, Hijikata-Okunomiya A, Naito T, Okamoto S.
    Chem Pharm Bull (Tokyo); 1991 Nov 15; 39(11):2930-6. PubMed ID: 1839246
    [Abstract] [Full Text] [Related]

  • 8. A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC.
    Okamoto S, Wanaka K, Hijikata-Okunomiya A, Okada Y, Katsuura Y.
    Agents Actions Suppl; 1992 Nov 15; 38 ( Pt 1)():198-205. PubMed ID: 1466271
    [Abstract] [Full Text] [Related]

  • 9. Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
    Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J.
    Thromb Haemost; 2003 May 15; 89(5):820-5. PubMed ID: 12719778
    [Abstract] [Full Text] [Related]

  • 10. Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.
    Fujimori Y, Nakamura T, Shimizu K, Yamamuro T, Wanaka K, Okamoto S, Katsuura Y.
    Agents Actions; 1993 May 15; 39(1-2):42-8. PubMed ID: 8285139
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein.
    Tsuda Y, Teno N, Okada Y, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, Okamoto U, Naito T, Okamoto S.
    Chem Pharm Bull (Tokyo); 1989 Nov 15; 37(11):3108-11. PubMed ID: 2534361
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synthesis of peptides of arginine chloromethyl ketone. Selective inactivation of human plasma kallikrein.
    Kettner C, Shaw E.
    Biochemistry; 1978 Oct 31; 17(22):4778-84. PubMed ID: 728386
    [Abstract] [Full Text] [Related]

  • 16. Synergistic antithrombotic effect of a combination of NO donor and plasma kallikrein inhibitor.
    Ikarugi H, Inoue A, Yamashita T, Tsuda Y, Okada Y, Ishii H, Yamamoto J.
    Thromb Res; 2005 Oct 31; 116(5):403-8. PubMed ID: 16122553
    [Abstract] [Full Text] [Related]

  • 17. Design of kallidin-releasing tissue kallikrein inhibitors based on the specificities of the enzyme's binding subsites.
    Portaro FC, Cezari MH, Juliano MA, Juliano L, Walmsley AR, Prado ES.
    Biochem J; 1997 Apr 01; 323 ( Pt 1)(Pt 1):167-71. PubMed ID: 9173877
    [Abstract] [Full Text] [Related]

  • 18. Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis.
    Gohda K, Teno N, Wanaka K, Tsuda Y.
    J Enzyme Inhib Med Chem; 2012 Aug 01; 27(4):571-7. PubMed ID: 21992704
    [Abstract] [Full Text] [Related]

  • 19. Enzyme-controlling medicines: introduction.
    Okamoto S, Hijikata-Okunomiya A, Wanaka K, Okada Y, Okamoto U.
    Semin Thromb Hemost; 1997 Aug 01; 23(6):493-501. PubMed ID: 9469621
    [Abstract] [Full Text] [Related]

  • 20. New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase.
    Morita T, Kato H, Iwanaga S, Takada K, Kimura T.
    J Biochem; 1977 Nov 01; 82(5):1495-8. PubMed ID: 591514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.